239 related articles for article (PubMed ID: 21920019)
1. MELD Exceptions and Rates of Waiting List Outcomes.
Massie AB; Caffo B; Gentry SE; Hall EC; Axelrod DA; Lentine KL; Schnitzler MA; Gheorghian A; Salvalaggio PR; Segev DL
Am J Transplant; 2011 Nov; 11(11):2362-71. PubMed ID: 21920019
[TBL] [Abstract][Full Text] [Related]
2. Excess mortality on the liver transplant waiting list: unintended policy consequences and Model for End-Stage Liver Disease (MELD) inflation.
Northup PG; Intagliata NM; Shah NL; Pelletier SJ; Berg CL; Argo CK
Hepatology; 2015 Jan; 61(1):285-91. PubMed ID: 24995689
[TBL] [Abstract][Full Text] [Related]
3. Impact of major hepatocellular carcinoma policy changes on liver transplantation for hepatocellular carcinoma in the United States.
Shah RH; Chyou D; Goldberg DS
Liver Transpl; 2022 Dec; 28(12):1857-1864. PubMed ID: 35585774
[TBL] [Abstract][Full Text] [Related]
4. Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era.
Berg CL; Merion RM; Shearon TH; Olthoff KM; Brown RS; Baker TB; Everson GT; Hong JC; Terrault N; Hayashi PH; Fisher RA; Everhart JE
Hepatology; 2011 Oct; 54(4):1313-21. PubMed ID: 21688284
[TBL] [Abstract][Full Text] [Related]
5. HCC patients suffer less from geographic differences in organ availability.
Schuetz C; Dong N; Smoot E; Elias N; Schoenfeld DA; Markmann JF; Yeh H
Am J Transplant; 2013 Nov; 13(11):2989-95. PubMed ID: 24011291
[TBL] [Abstract][Full Text] [Related]
6. Impact of MELD 30-allocation policy on liver transplant outcomes in Italy.
Ravaioli M; Lai Q; Sessa M; Ghinolfi D; Fallani G; Patrono D; Di Sandro S; Avolio A; Odaldi F; Bronzoni J; Tandoi F; De Carlis R; Pascale MM; Mennini G; Germinario G; Rossi M; Agnes S; De Carlis L; Cescon M; Romagnoli R; De Simone P
J Hepatol; 2022 Mar; 76(3):619-627. PubMed ID: 34774638
[TBL] [Abstract][Full Text] [Related]
7. Liver Transplantation in France.
Durand F; Antoine C; Soubrane O
Liver Transpl; 2019 May; 25(5):763-770. PubMed ID: 30697904
[TBL] [Abstract][Full Text] [Related]
8. Proposal of a novel MELD exception point system for hepatocellular carcinoma based on tumor characteristics and dynamics.
Bhat M; Ghali P; Dupont B; Hilzenrat R; Tazari M; Roy A; Chaudhury P; Alvarez F; Carrier M; Bilodeau M
J Hepatol; 2017 Feb; 66(2):374-381. PubMed ID: 27751840
[TBL] [Abstract][Full Text] [Related]
9. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
[TBL] [Abstract][Full Text] [Related]
10. Regional Variation in Appropriateness of Non-Hepatocellular Carcinoma Model for End-Stage Liver Disease Exception.
Cannon RM; Davis EG; Goldberg DS; Lynch RJ; Shah MB; Locke JE; McMasters KM; Jones CM
J Am Coll Surg; 2020 Apr; 230(4):503-512.e8. PubMed ID: 32007535
[TBL] [Abstract][Full Text] [Related]
11. Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.
Goldberg D; French B; Abt P; Feng S; Cameron AM
Liver Transpl; 2012 Apr; 18(4):434-43. PubMed ID: 22271656
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses.
Wey A; Noreen S; Gentry S; Cafarella M; Trotter J; Salkowski N; Segev D; Israni A; Kasiske B; Hirose R; Snyder J
Liver Transpl; 2022 Mar; 28(3):363-375. PubMed ID: 34482614
[TBL] [Abstract][Full Text] [Related]
13. Effect of Mandatory 6-Month Waiting Period on Waitlist and Transplant Outcomes in Patients With Hepatocellular Carcinoma.
Nagai S; Kitajima T; Yeddula S; Salgia R; Schilke R; Abouljoud MS; Moonka D
Hepatology; 2020 Dec; 72(6):2051-2062. PubMed ID: 32157711
[TBL] [Abstract][Full Text] [Related]
14. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy.
Cejas NG; Villamil FG; Lendoire JC; Tagliafichi V; Lopez A; Krogh DH; Soratti CA; Bisigniano L
Liver Transpl; 2013 Jul; 19(7):711-20. PubMed ID: 23775946
[TBL] [Abstract][Full Text] [Related]
15. Waiting list outcome of Peld/Meld exceptions: A single-center experience in Argentina.
Lauferman L; Dip M; Halac E; Cervio G; Aredes D; Capparelli M; Reijenstein H; Minetto J; Rojas L; Goñi J; Jacobo Dillon A; Martinitto R; Imventarza O
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29297966
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for hepatocellular carcinoma: the MELD impact.
Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
[TBL] [Abstract][Full Text] [Related]
17. Impact of Median MELD at Transplant Minus 3 National Policy on Quality of Transplanted Livers for Patients With and Without Hepatocellular Carcinoma.
Mazur RD; Cron DC; Chang DC; Yeh H; Dageforde LAD
Transplantation; 2024 Jan; 108(1):204-214. PubMed ID: 37189232
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
Taniguchi M
Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
[TBL] [Abstract][Full Text] [Related]
19. Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.
Ishaque T; Massie AB; Bowring MG; Haugen CE; Ruck JM; Halpern SE; Waldram MM; Henderson ML; Garonzik Wang JM; Cameron AM; Philosophe B; Ottmann S; Rositch AF; Segev DL
Am J Transplant; 2019 Feb; 19(2):564-572. PubMed ID: 30312530
[TBL] [Abstract][Full Text] [Related]
20. Regional Social Vulnerability is Associated With Geographic Disparity in Waitlist Outcomes for Patients With Non-Hepatocellular Carcinoma Model for End-stage Liver Disease Exceptions in the United States.
Cannon RM; Goldberg DS; Sheikh SS; Anderson DJ; Pozo M; Rabbani U; Locke JE
Ann Surg; 2024 May; 279(5):825-831. PubMed ID: 37753656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
